Last updated on December 2018

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

Brief description of study

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Clinical Study Identifier: NCT02929329

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Sopron, Hungary
  Connect »